Qube Research & Technologies LTD Tricida, Inc. Transaction History

Qube Research & Technologies LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.14 - $12.49 $8,056 - $718,787	-57,549 Reduced 58.29%	41,184 $6,000
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $840,217 - $1.34 Million	98,733 New	98,733 $1.04 Million
Q2 2022 Aug 15, 2022	SELL	$7.31 - $11.85 $322,634 - $523,011	-44,136 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$7.35 - $10.63 $47,201 - $68,265	6,422 Added 17.03%	44,136 $363,000
Q4 2021 Feb 01, 2022	BUY	$4.19 - $9.56 $158,021 - $360,545	37,714 New	37,714 $361,000
Q4 2020 Feb 16, 2021	SELL	$4.37 - $9.46 $80,189 - $173,591	-18,350 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$8.56 - $26.93 $157,076 - $494,165	18,350 New	18,350 $166,000
Q1 2020 May 15, 2020	SELL	$18.43 - $38.04 $152,987 - $315,770	-8,301 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$29.6 - $43.71 $245,709 - $362,836	8,301 New	8,301 $313,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.